Device Cardiovascular

Lariat Rs

Payments companies reported to CMS as associated with Lariat Rs. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$90Kassociated payments (2023-2025)
55clinicians with associated payments
2companies reporting

By year

2023 $20K
2024 $68K
2025 $2,397

Payments reported as associated with Lariat Rs, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Thoracic Surgery (Cardiothoracic Vascular Surgery) $56K
Clinical Cardiac Electrophysiology $23K
Advanced Heart Failure and Transplant Cardiology $7,500
Surgical $2,149
Physician Assistant $563
Interventional Cardiology $251

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Lariat Rs

These are the largest totals companies reported as associated with Lariat Rs. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Armin Kiankhooy Saint Helena, CA Thoracic Surgery (Cardiothoracic Vascular Surgery) $37,500.00
Nitish Badhwar Stanford, CA Clinical Cardiac Electrophysiology $9,076.00
Ahmed Romeya Big Spring, TX Thoracic Surgery (Cardiothoracic Vascular Surgery) $8,000.00
Peter Fail Houma, LA Advanced Heart Failure and Transplant Cardiology $7,500.00
Jonathan Praeger Los Angeles, CA Thoracic Surgery (Cardiothoracic Vascular Surgery) $6,999.08
Kent Morris Louisville, KY Clinical Cardiac Electrophysiology $5,713.22
Ronald Moore Celebration, FL Surgical $2,123.95
Abdi Rasekh Houston, TX Clinical Cardiac Electrophysiology $1,608.21
Miguel Valderrabano Houston, TX Clinical Cardiac Electrophysiology $1,290.87
Andrea Natale Austin, TX Clinical Cardiac Electrophysiology $1,290.86

Prescribed Lariat Rs?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.